Halozyme Expands argenx Deal to Eight Exclusive ENHANZE Targets
Image
San Diego – – October 06, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) has expanded its global collaboration and license agreement with argenx, adding two new exclusive targets for its ENHANZE drug-delivery platform and raising the partner's total exclusive target count from six to eight.
Halozyme adds two exclusive ENHANZE targets to argenx licensing deal
The expanded agreement builds on the companies' existing collaboration, which already delivered VYVGART Hytrulo, a subcutaneous treatment for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Under the new terms, Halozyme is eligible for milestone payments tied to development and regulatory progress on the additional targets, plus royalties on future net sales of any resulting products using ENHANZE.